XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

Manhattanites are flocking to restaurants that are being compared to Applebee's and TGI Friday's in search of simple meals - ...

CMS has published its final rule for Medicare Advantage and Part D in 2026, outlining a series of regulatory updates aimed at ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

Proponents of coverage argued treating obesity can reduce longer-term costs by cutting down on heart attacks and other health ...

“France has done a lot to tackle obesity, but now it must go one step further and recognise obesity as a disease,” says ...

The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...